UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: March 29, 2013

VISUALANT, INCORPORATED

(Exact name of Registrant as specified in its charter)

<u>Nevada</u> (State or jurisdiction of incorporation) 0-25541 (Commission File No.)

500 Union Street, Suite 420 Seattle, Washington 98101 (206) 903-1351

(Address of Registrant's principal executive office and telephone number)

Section 8 – Other Events

Item 8.01 Other Events.

On April I, 2013, Visualant, Inc. (the "Company"), an industry-leading provider of chromatic-based authentification, identification and diagnostic solutions, announced today that it received its fifth patent on its ChromaIDTM technology. The latest patent further validates the company's vision to introduce more efficient authentication, identification and diagnostic methods into the marketplace, and comes shortly after Visualant was awarded the prestigious PRISM award at the SPIE Photonics West trade show in San Francisco.

Future devices embedded with ChromaID[™] technology can read and record natural chromatic markers by structuring light onto a substance, through a liquid or gas, or off a surface. Once scanned, the technology captures the reflected light using a simple Photodiode array and creates a unique ChromaID profile. The ChromaID profile can be matched against existing databases to identify, detect, or diagnosis markers invisible to the human eye. The latest patent extends the reach of Visualant's intellectual property to cover medical diagnostics.

The patent issued by the United States Office of Patents and Trademarks is US Patent No. 8,368,878 B2 and is entitled "Method, Apparatus and Article To Facilitate Evaluation of Object Using Electromagnetic Energy."

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits -Description Exhibit No. Press Release of Visualant, Inc. dated April 1, 2013 related to a fifth patent award for the ChromaID[™] technology. 99.1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Registrant: VISUALANT, INCORPORATED April 1, 2013 By: /s/ Mark Scott Mark Scott, CFO EXHIBIT INDEX Exhibit No. Description 99.1 Press Release of Visualant, Inc. dated April 1, 2013 related to a fifth patent award for the ChromaID[™] technology.

- 2 -

VISUALANT

Visualant Awarded Fifth Patent for its ChromaID[™] Technology

Latest patent further strengthens market opportunity for devices using ChromaID scanners and extends the reach of Visualant's IP to medical diagnostics

Seattle, WA. – (April 1, 2013) Visualant, Inc. (OTCBB: VSUL) – an industry-leading provider of chromaticbased authentification, identification and diagnostic solutions, announced today that it received its fifth patent on its ChromaIDTM technology. The latest patent further validates the company's vision to introduce more efficient authentication, identification and diagnostic methods into the marketplace, and comes shortly after Visualant was awarded the prestigious PRISM award at the SPIE Photonics West trade show in San Francisco.

Future devices embedded with ChromaID technology can read and record natural chromatic markers by structuring light onto a substance, through a liquid or gas, or off a surface. Once scanned, the technology captures the reflected light using a simple Photodiode array and creates a unique ChromaID profile. The ChromaID profile can be matched against existing databases to identify, detect, or diagnosis markers invisible to the human eye. The latest patent extends the reach of Visualant's intellectual property to cover medical diagnostics.

The patent issued by the United States Office of Patents and Trademarks is US Patent No. 8,368,878 B2 and is entitled "Method, Apparatus and Article To Facilitate Evaluation of Object Using Electromagnetic Energy."

Ron Erickson, Visualant Founder and CEO, stated, "We rigorously pursue strong protection for our intellectual property. We are very pleased to receive this, our fifth patent. I want to especially acknowledge our Visualant scientific team led by Dr. Tom Furness and Dr. Brian Schowengerdt. We have more patents pending and expect more patents to be issued as we build the intellectual property foundation for Visualant's business and move into the marketplace with diverse applications of our ChromaID technology."

About Visualant, Inc.

VisualantTM is a public company whose shares trade under the stock symbol, VSUL. The Visualant Spectral Pattern MatchingTM technology directs structured light onto a substance, through a liquid/gas, or off a surface, to capture a unique ChromaIDTM. When matched against existing databases, a ChromaID can be used to identify, detect, or diagnosis markers invisible to the human eye. ChromaID scanner modules can be integrated into a variety of mobile or fixed-mount form factors. The patented technology is disruptive, making it possible to effectively conduct analyses in the field that could only previously be performed by large and expensive lab–based tests.

Visualant entered into a one year Joint Development Agreement on May 31, 2012 with Sumitomo Precision Products Co., Ltd. ("SPP"), which focuses on the commercialization of the SPM technology and a License Agreement providing SPP with an exclusive license of the SPM technology in identified Asian territories. For more information, visit http://www.visualant.net.

Sumitomo Precision Products Co., Ltd. is publicly traded on the Tokyo and Osaka Stock Exchanges and has operations in Japan, United States, China, United Kingdom, Canada, and other parts of the world. Additional information on SPP is available at www.spp.co.jp/English/index2-e.html.

Press contacts

Hal Bringman hal@nvpr.com +1 (206) 299-0622 ext 801 +1 (310) 210-8011 *Skype*: halbringman

Tina Qunell tina@nvpr.com +1 (206) 919-9652